Based on the Sutro Biopharma stock forecast from 5 analysts, the average analyst target price for Sutro Biopharma is USD 7.13 over the next 12 months. Sutro Biopharma’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Sutro Biopharma is Bearish, which is based on 1 positive signals and 8 negative signals. At the last closing, Sutro Biopharma’s stock price was USD 0.88. Sutro Biopharma’s stock price has changed by -8.33% over the past week, +51.60% over the past month and -77.65% over the last year.
No recent analyst target price found for Sutro Biopharma
No recent average analyst rating found for Sutro Biopharma
Company Overview Sutro Biopharma
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. Read Less
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its...Read More
Frequently Asked Questions About Sutro Biopharma (STRO) Stock
Based on ratings from 5 analysts Sutro Biopharma's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, 1 sell and 3 hold ratings.
Unfortunately we do not have enough data on STRO's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for STRO is USD 7.13 over the next 12 months. The maximum analyst target price is USD 17 while the minimum anlayst target price is USD 1.
STRO stock's Price/Earning ratio is 56.60.
Our analysis grades STRO stock's Price / Earning ratio at F. This means that STRO stock's Price/Earning ratio is above 85% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this STRO may be a overvalued for its sector.
The last closing price of STRO's stock was USD 0.88.
The most recent market capitalization for STRO is USD 0.05B.
Based on targets from 5 analysts, the average taret price for STRO is projected at USD 7.13 over the next 12 months.
This means that STRO's stock price may go up by +711.04% over the next 12 months.
We can't find any ETFs which contains Sutro Biopharma's stock.
As per our most recent records Sutro Biopharma has 310 Employees.
Sutro Biopharma's registered address is 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Sutro Biopharma's website at https://www.sutrobio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Sutro Biopharma (STRO) Stock
Based on ratings from 5 analysts Sutro Biopharma's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, 1 sell and 3 hold ratings.
Unfortunately we do not have enough data on STRO's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for STRO is USD 7.13 over the next 12 months. The maximum analyst target price is USD 17 while the minimum anlayst target price is USD 1.
STRO stock's Price/Earning ratio is 56.60.
Our analysis grades STRO stock's Price / Earning ratio at F. This means that STRO stock's Price/Earning ratio is above 85% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this STRO may be a overvalued for its sector.
The last closing price of STRO's stock was USD 0.88.
The most recent market capitalization for STRO is USD 0.05B.
Based on targets from 5 analysts, the average taret price for STRO is projected at USD 7.13 over the next 12 months.
This means that STRO's stock price may go up by +711.04% over the next 12 months.
We can't find any ETFs which contains Sutro Biopharma's stock.
As per our most recent records Sutro Biopharma has 310 Employees.
Sutro Biopharma's registered address is 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Sutro Biopharma's website at https://www.sutrobio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for STRO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
